Table 2.

Baseline characteristics of the studies included in this review

Studies	Country	Study design	Year of publication	Baseline comparison (Y/N)	Number of participants (TFL)	Mean age (years)	Follow-up
Delbarre et al. [10]	France	Prospective study	2023	Yes	100	60.1 ± 17.7	3 months
Singh A et al. [11]	India	Prospective clinical trial	2023	NR	76	NR	NR
Quiroz Madarriaga Y. et al. [12]	Europe and Asia	Prospective clinical trial	2023	NR	40	8.5	NR
Geavlete B. et al. [13]	Romania	Retrospective study	2022	Yes	59	48.94 ± 15.93	3 months
Soundarya G. et al. [14]	India	Prospective clinical trial	2022	NR	52	40.91 ± 12.62	5.98 ± 0.79 months
Sytnik D. et al. [15]	Russia	Prospective clinical trial	2022	Yes	12	NR
Taraktin M. et al. [4]	Russia	Prospective Clinical study	2022	Yes	153	54 ± 2.8	3 months
Vaddi C.M. et al. [16]	US	Prospective study	2022	Yes	126	45.04 ± 12.30	3 months
Sierra et al. [17]	Japan	Prospective study	2021	Yes	50	55(44–61.5)	NR
Taraktin M. et al. [18]	Russia	Retrospective study	2021	NR	14	NR	3 months
Enikeev D. et al. [19]	Russia	Prospective study	2020	Yes	40	56	3 months
Korolev D. et al. [20]	Russia	Clinical study	2020	NR	130	NR	NR